Conclusion
The recognition of NTRK as a potential oncogene is now dated, the proper
understanding of the specific mechanisms involved and their appreciation
as a potential therapeutic target is far more recent. NTRK inhibitors
have shown high efficacy in multiple NTRK-driven cancers shining the
concept of ”targeted therapy”.
This case illustrates the response seen in pediatric intramedullary
spinal cord LGGs with NTKA2 fusion treated with Larotrectinib. This
case’s findings are similar to the findings of a clinical trial that was
conducted for 24 patients, highlighting the potential of targeted
therapies in pediatric patients when oncogenic drivers can be identified
and selective inhibitors are available. Accordingly, our case suggests
the use of the multi-layer diagnosis integrating histopathology and
molecular genetics analysis could have significant prognostic
implications.